Search company, investor...
Psygen company logo


Founded Year


About Psygen

Psygen is a manufacturer of pharmaceutical-grade psychedelic drug products for clinical research and therapeutic applications.

Headquarters Location

Calgary, Alberta,


Psygen's Product Videos

Compete with Psygen?

Ensure that your company and products are accurately represented on our platform.

Psygen's Products & Differentiators

    Psychedelic APIs

    With patents pending for our improved production methods, Psygen provides high quality, GMP, synthetic psychedelics for use in clinical trials, academic research and special medical access programs (e.g. SAP in Canada) around the world. Our products include Psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, LSD, 2C-B, and mescaline.

Expert Collections containing Psygen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Psygen is included in 1 Expert Collection, including Psychedelics.



247 items

Latest Psygen News

Psygen Receives Dealer's Licence from Health Canada

Jan 17, 2022

Global Reach for Canada's Only Dedicated Manufacturer of Synthetic Psychedelics Calgary, Alberta--(Newsfile Corp. - January 17, 2022) - Psygen Industries Ltd. (together with its subsidiaries, "Psygen") is pleased to announce that its wholly-owned subsidiary, Psygen Labs Inc., received a dealer's licence issued by Health Canada on January 17, 2022 (the "Dealer's Licence"). Upon completion of its facility in Calgary, Psygen will begin onsite manufacturing of synthetic psychedelics in accordance with Good Manufacturing Practices ("GMP") for use in clinical and scientific research. Psygen is strongly positioned to manufacture at scale any psychedelic drug substance that the market demands. "Psygen's dealer's licence is a major milestone that opens the doors to commercial production of GMP psilocybin and other psychedelics at our facility. Our dealer's licence issued following a perfect inspection, meaning we had zero observations from the inspector, which is indicative of the diligence and skill that Psygen brings to our work," said Danny Motyka, CEO of Psygen. Psygen's dealer's licence authorizes Psygen to manufacture, sell, import, export and otherwise deal with the following controlled substances: lysergic acid diethylamide ("LSD") mescaline In addition to focusing on the controlled substances listed above, Psygen manufactures high-potential unscheduled substances such as 5-methoxy-N,N-dimethyltryptamine ("5-MeO-DMT"), ibogaine and others. Psygen has over twenty supply agreements in place for psilocybin, DMT, ibogaine, 5-MeO-DMT, MDMA and LSD to be fulfilled globally from production at the Psygen facility. GMP psilocybin previously manufactured by Psygen personnel in collaboration with a licensed dealer using Psygen's methods has already been used in clinical trials for development of therapeutic products. Psygen also provided Health Canada with consent to be identified on a public list as a licensed dealer able to provide GMP psilocybin for use in patients through Canada's special access program (the "SAP"). On January 5, 2022, the Food and Drug Regulations (Canada) were amended to allow access to restricted drugs such as psilocybin and MDMA through the SAP. "A primary application for psychedelics is to support psychotherapy for treatment of mental health conditions. After two years of a global pandemic, mental health conditions are a more urgent need than ever. We are excited to supply material for use in clinical trials and the SAP to further validate the utility of psychedelic medicines," said Peter van der Heyden, Chief Science Officer of Psygen. About Psygen Psygen is a privately-held licensed dealer and active pharmaceutical ingredient ("API") manufacturer based in Calgary, Alberta. Psygen's dealer's licence authorizes possession, manufacture, sale, import, export and otherwise dealing with LSD, MDMA, psilocybin, psilocin, DMT, 2C-B and mescaline. Psygen is positioned to be a leader in manufacturing and sale of synthetic psychedelic APIs for healing and wellness in compliance with applicable laws. Psygen manufactures pharmaceutical-grade psychedelic drug substances in accordance with GMP for clinical research and other therapeutic applications. Psygen's APIs have been sold to, and used by, drug development companies, academic institutions and other authorized persons domestically and internationally. Psygen consists of a team of industry and business experts with over 50 years of direct experience in manufacturing psychedelics. Psygen's team has experience synthesizing an industry-leading variety of psychedelic compounds, and experience manufacturing LSD, psilocybin and MDMA at scale. Psygen's licensed facility is Canada's first dedicated synthetic psychedelics manufacturing facility with authorization for the synthesis of a variety of psychedelic drugs for clinical research and approved therapeutic applications. Cautionary Statements Regarding Forward-Looking Information This press release contains "forward-looking information" within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking statements or information. Forward-looking statements and information in this press release includes, but is not limited to, anticipated completion of the Psygen facility in Calgary, the anticipated onsite manufacturing, sale, import, and export of synthetic psychedelics and controlled substances in accordance with GMP standards, and the fulfillment of various supply agreements. Although Psygen believes that the expectations and assumptions on which the forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because Psygen cannot give any assurance that they will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the timing of completion of Psygen's facility, the successful operation of the facility and the application of Psygen's key manufacturing and analytical processes to manufacturing. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Psygen cautions that the foregoing list of risks and uncertainties is not exhaustive. The forward-looking statements and information contained in this news release are made as of the date hereof and Psygen undertakes no obligation to update publicly or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise unless so required by applicable securities laws. For more information, please contact: Psygen Industries Ltd.

Psygen Frequently Asked Questions (FAQ)

  • When was Psygen founded?

    Psygen was founded in 2019.

  • Where is Psygen's headquarters?

    Psygen's headquarters is located at Calgary.

  • Who are Psygen's competitors?

    Competitors of Psygen include Dalton Pharma Services and 4 more.

  • What products does Psygen offer?

    Psygen's products include Psychedelic APIs and 2 more.

  • Who are Psygen's customers?

    Customers of Psygen include TheraPsil.

Compare Psygen to Competitors

Onyx Scientific Logo
Onyx Scientific

Onyx Scientific Ltd supplies pharmaceutical and biotechnology companies with chemistry research services to enable new leads to be discovered, developed and optimised. Through collaboration with several universities, Onyx has proprietary rights which allow it to work better with several types of chiral molecules and unnatural amino acids.

Usona Institute Logo
Usona Institute

Usona Institute conducts pre-clinical and clinical research to further the understanding of the therapeutic effects of psilocybin and other consciousness-expanding medicines.

PharmAla Biotech Logo
PharmAla Biotech

PharmAla Biotech operates as a biotechnology company. It provides domestic research and development and sourcing of clinical-grade LaNeo MDMA and novel MDXX compounds in service to the scientific research community. It was founded in 2021 and is based in Toronto, Canada.

Benuvia Manufacturing

Benuvia Manufacturing is a company that develops and manufactures pharmaceutical cannabinoid ingredients and products. It offers a comprehensive suite of solutions for pharmaceutical, biotechnology, and consumer product companies to achieve their development and commercial needs. It was founded in 2020 and is based in Round Rock, Texas.

Dalton Pharma Services

Dalton Pharma Services is a cGMP contract service provider of integrated drug discovery, development and manufacturing services to the pharmaceutical and biotechnology industries. The company delivers fully integrated solutions with an emphasis on speed, flexibility, and quality. Its integrated services (drug discovery, formulation and process development, custom synthesis, cGMP sterile fill/finish of liquids and powders, cGMP API manufacturing and/or dosage form manufacturing, and Accelerated Stability Testing) all at one location help it to be adaptable, flexible, and cost-effective.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.